The proof-of-concept, which will be exhibited at the Singapore Fintech Festival from Nov. 6-8, demonstrates how investors could settle multi-asset positions in real-time.
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the completion of a $115 million Series C ...